Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.09 | N/A | +90.02% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.09 | N/A | +90.02% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed cautious optimism about the future. They noted the importance of continued focus on their strategic initiatives.
Management highlighted the positive surprise in EPS despite the lack of revenue guidance.
They emphasized ongoing efforts in product development and market positioning.
This earnings report shows that Soleno Therapeutics managed to exceed expectations on EPS, which is a positive sign for the company. However, the stock reacted negatively, declining by 0.54%. The lack of revenue figures and guidance may have contributed to investor uncertainty.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SIMON PPTY GROUP INC REIT
Aug 4, 2025